Given the importance of type-I LRRK2 inhibitors in the current PD-related clinical trials, as well as the different effects on LRRK2–microtubule association induced by type-I and type-II LRRK2 inhibitors, it is important to determine whether autoinhibited LRRK2 can bind to microtubules and, if it does, to understand the association structurally. This evidence concerns the gene LRRK2 and Parkinson disease.